These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 33548518)

  • 1. Treatment Effect of the Tree Pollen SLIT-Tablet on Allergic Rhinoconjunctivitis During Oak Pollen Season.
    Nolte H; Waserman S; Ellis AK; Biedermann T; Würtzen PA
    J Allergy Clin Immunol Pract; 2021 May; 9(5):1871-1878. PubMed ID: 33548518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.
    Mäkelä MJ; Gyllfors P; Valovirta E; Steffensen MA; Grønager PM; Savolainen J; Winther L
    Clin Ther; 2018 Apr; 40(4):574-586.e4. PubMed ID: 29551533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Biedermann T; Kuna P; Panzner P; Valovirta E; Andersson M; de Blay F; Thrane D; Jacobsen SH; Stage BS; Winther L
    J Allergy Clin Immunol; 2019 Mar; 143(3):1058-1066.e6. PubMed ID: 30654054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplified AIT for allergy to several tree pollens-Arguments from the immune outcome analyses following treatment with SQ tree SLIT-tablet.
    Würtzen PA; Grønager PM; Lund G; Gupta S; Andersen PS; Biedermann T; Ipsen H
    Clin Exp Allergy; 2021 Feb; 51(2):284-295. PubMed ID: 33207015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG
    Couroux P; Ipsen H; Stage BS; Damkjaer JT; Steffensen MA; Salapatek AM; Lund K; Würtzen PA
    Allergy; 2019 Feb; 74(2):361-369. PubMed ID: 30229939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
    Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
    Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
    Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
    J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of the SQ Tree SLIT Tablet in Adults.
    Birk AO; Andersen JS; Villesen HH; Steffensen MA; Calderon MA
    Clin Ther; 2017 Sep; 39(9):1858-1867. PubMed ID: 28844318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial.
    Nolte H; Bernstein DI; Nelson HS; Ellis AK; Kleine-Tebbe J; Lu S
    J Allergy Clin Immunol Pract; 2020; 8(7):2322-2331.e5. PubMed ID: 32304832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells specific to multiple Bet v 1 peptides are highly cross-reactive toward the corresponding peptides from the homologous group of tree pollens.
    Lund G; Christensen LH; Ihlemann J; Andersen PS; Wambre E; Würtzen PA; Gupta S
    Front Immunol; 2023; 14():1291666. PubMed ID: 38077382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
    Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
    J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis.
    Nelson HS; Bernstein DI; Biedermann T; Nolte H
    Allergy Asthma Proc; 2024 Jan; 45(1):33-36. PubMed ID: 38151733
    [No Abstract]   [Full Text] [Related]  

  • 14. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
    Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
    Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis.
    Devillier P; Dreyfus JF; Demoly P; Calderón MA
    BMC Med; 2014 May; 12():71. PubMed ID: 24885894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Artemisia annua sublingual immunotherapy in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons.
    Yang J; Wang W; Shen Z; Kang W; Zhang P; Chen X; Li H; Shao Y; Liu L; Zhang S; Quan F
    Eur Arch Otorhinolaryngol; 2023 Nov; 280(11):4939-4947. PubMed ID: 37365351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
    Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
    J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.